UGT1A1 Genotype
The UGT1A1 genotype is a pharmacogenomic biomarker that determines how efficiently the UGT1A1 enzyme metabolizes certain drugs and toxins, particularly irinotecan.
UGT1A1 genotype predicts the risk of adverse reactions to medications like irinotecan.
Key facts at a glance
- Units
- genotype
- Clinical utility
- predictive
- Result kind
- qualitative
- FDA-cleared
- Roche UGT1A1, Abbott UGT1A1, Esoterix UGT1A1
The UGT1A1 gene encodes the uridine diphosphate glucuronosyltransferase 1A1 enzyme, which plays a crucial role in the metabolism of substances like bilirubin and various drugs, including the chemotherapy agent irinotecan.
Variations in the UGT1A1 gene, such as the *28 allele, can lead to reduced enzyme activity, affecting the rate at which drugs are metabolized and potentially increasing the risk of adverse reactions.
Testing for UGT1A1 genotype can help clinicians tailor medication dosages or choose alternative treatments to minimize toxicity and improve patient outcomes.
Frequently asked questions
What is the clinical significance of UGT1A1 genotyping?
How is UGT1A1 genotyping performed?
Sources
- 1
- 2
Click any link to access the full source. PubMed Central (PMC) links provide free full-text access.
This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed August 25, 2026. · Read our editorial policy